Back

Cardiovascular toxicities reported with Poly ADP Ribose Polymerase (PARP) inhibitors in the FDA Adverse Event Reporting System

21 June 2025 (16:05 - 16:50)
Organised by: Logo
Congress Presentation Part of: Innovations and new insights in cardio oncology Diagnosis and Management of Cardiovascular Disease in Patients with Cancer CCO Premium Access ESC Cardio-Oncology 2025 Council of Cardio-Oncology

About the speaker

Photo
Doctor Angela Boccia

University Of Bologna - Bologna (Italy)

5 More presentations in this session

Presentation thumbnail
Reducing administrative burden in cardio-oncology: an LLM-powered approach for automated summarization of oncology and cardiotoxicity histories in dutch medical records
Doctor J. Heemelaar (Leiderdorp, NL)
Abstract
Presentation thumbnail
Characteristics of patients with nonbacterial thrombotic endocarditis and factors associated with occurrence of embolic events and prognosis
Assistant Professor S. Gwak (Seoul, KR)
Abstract Slides
Presentation thumbnail
Acute myeloid leukemia with KMT2A rearrangements in children with congenital heart disease: case series and literature review
Doctor G. Wu (Tao-Yuan, TW)
Abstract Slides
Presentation thumbnail
Does the short-term cardioprotection prevent diastolic dysfunction?
Doctor M. Del Bene (Florence, IT)
Abstract Slides
Presentation thumbnail
Dosimetric evaluation of cardiac substructures in DIBH-VMAT and FB- VMAT in hypofractionated radiotherapy for left-sided breast cancer: a comparative planning study
Doctor S. Rana (Gurugram, IN)
Abstract Slides

Access the full session

Session thumbnail
Innovations and new insights in cardio oncology

The Event

Event poster

ESC Cardio-Oncology 2025

21 June 2025 16:05 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources